|
Addition of Xeloda to Herceptin and Docetaxel
San Antonio, Texas (ots/PRNewswire) - New data presented today atthe San Antonio Breast Cancer Symposium (SABCS) show that addingXeloda (capecitabine) to the current gold standard combination ofHerceptin (trastuzumab) and docetaxel allows patients with advancedHER2-positive breast cancer to live, on average 5 months longer untiltheir cancer starts to grow. The addition of capecitabine in thissetting represents an important advance in the treatment of anaggressive form of breast cancer and provides additional hope towomen with an otherwise poor prognosis
full article: http://www.juraforum.de/jura/news/ne.../210140/f/109/
__________________
Kate
Stage IIIC Diagnosed Oct 25, 2005 (age 58)
ER/PR-, HER2+++, grade 3, Ploidy/DNA index: Aneuploid/1.61, S-phase: 24.2%
Neoadjunct chemo: 4 A/C; 4 Taxatore
Bilateral mastectomy June 8, 2006
14 of 26 nodes positive
Herceptin June 22, 2006 - April 20, 2007
Radiation (X35) July 24-September 11, 2006
BRCA1/BRCA2 negative
Stage IV lung mets July 13, 2007 - TCH
Single brain met - August 6, 2007 -CyberKnife
Oct 2007 - clear brain MRI and lung mets shrinking.
March 2008 lung met progression, brain still clear - begin Tykerb/Xeloda/Ixempra
|